Zobrazeno 1 - 10
of 26
pro vyhledávání: '"and Heather K. Webb"'
Publikováno v:
Molecular pharmacology, vol 84, iss 6
Soluble epoxide hydrolase (sEH) catalyzes the conversion of epoxyeicosatrienoic acids into less active eicosanoids, and inhibitors of sEH have anti-inflammatory and antiapoptotic properties. Based on previous observations that sEH inhibition attenuat
Autor:
Vinh Tran, Sampath K. Anandan, Dawn Chen, Zung N. Do, James Sabry, Heather K. Webb, Randall Whitcomb, Richard D. Gless, Euan MacIntyre, Dinesh V. Patel
Publikováno v:
Journal of Clinical Pharmacology
Journal of Clinical Pharmacology, Wiley, 2012, 52, pp.319-328
Journal of Clinical Pharmacology, Wiley, 2012, 52, pp.319-328
AR9281, a potent and selective inhibitor of soluble epoxide hydrolase (s-EH), is in clinical development targeting hypertension and type 2 diabetes. The safety, pharmacokinetics, and pharmacodynamics of AR9281 were evaluated in double-blind, randomiz
Autor:
Yi-Xin Jim Wang, Richard D. Gless, D. Euan MacIntyre, Gabor Rubanyi, Le-Ning Zhang, Sampath-Kumar Anandan, Heather K. Webb, Dawn Chen, Jon Vincelette
Publikováno v:
European Journal of Pharmacology. 654:68-74
Endothelial dysfunction is a hallmark of, and plays a pivotal role in the pathogenesis of cardiometabolic diseases, including type II diabetes, obesity, and hypertension. It has been well established that epoxyeicosatrienoic acids (EETs) act as an en
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 19:1066-1070
Inhibition of soluble epoxide hydrolase has been proposed as a promising new pharmaceutical target for diseases involving hypertension and vascular inflammation. The most potent sEH inhibitors reported to date contain a urea or amide moiety as the ce
Autor:
Gregory R. Luedtke, Yuanying Anne Huang, Sundeep Dugar, Jose Carlos Chavez, Ramona Almirez, Sarvajit Chakravarty, Cheng Ping Mao, Ann M. Kapoun, Satyanarayana Medicherla, Gladys T. Muiru, Linda S. Higgins, Aaron N. Nguyen, Don Lim, Yu-Wang Liu, Heather K. Webb, Bruce Koppelman, Babu J. Mavunkel, Ying Feng, Andrew A. Protter
Publikováno v:
Pharmacology. 81:204-220
The effects of small-molecule p38 inhibitors in numerous models of different disease states have been published, including those of SD-282, an indole-5-carboxamide inhibitor. The aim of the present study was to evaluate the pharmacological activity o
Autor:
Glenn Mcenroe, Wolfgang Wick, Alison Murphy, Martin Uhl, Ann M. Kapoun, Andrew Lam, Heather K. Webb, Thomas-Toan Tran, Sundeep Dugar, Jonathan Axon, Steffen Aulwurm, Barry Patrick Hart, Linda S. Higgins, Jing Ying Ma, Venkataraman Sriram, Lisa Janssen, Sarvajit Chakravarty, Michael Weller, Darin E. Kizer, Andrew A. Protter, Darren H. Wong, Irene Kerr
Publikováno v:
Neuro-Oncology. 9:259-270
Transforming growth factor-beta (TGF-beta) is a proinvasive and immunosuppressive cytokine that plays a major role in the malignant phenotype of gliomas. One novel strategy of disabling TGF-beta activity in gliomas is to disrupt the signaling cascade
Autor:
Heather K. Webb, John P. Leonard, Don M. Benson, Wayne R. Godfrey, Yoonjin Cho, Steven Coutre, Ian W. Flinn, John C. Byrd, Richard R. Furman, Sissy Peterman, Jennifer R. Brown, Nina D. Wagner-Johnston, Albert S. Yu, Stephen E. Spurgeon, David W. Johnson, Roger G. Ulrich, Brad S. Kahl, Langdon L. Miller
Idelalisib (GS-1101, CAL-101), an oral inhibitor of phosphatidylinositol 3-kinase-δ, was evaluated in a phase I study in 64 patients with relapsed indolent non-Hodgkin lymphoma (iNHL). Patients had a median (range) age of 64 (32-91) years, 34 (53%)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::170751a3b2b4a35be4abfe512c6f8eae
https://europepmc.org/articles/PMC4260978/
https://europepmc.org/articles/PMC4260978/
Autor:
Heather K. Webb, Steven Coutre, Nina D. Wagner-Johnston, Albert S. Yu, Ian W. Flinn, Dave Johnson, Daniel Li, Richard R. Furman, John C. Byrd, Sissy Peterman, Thomas Jahn, Jennifer R. Brown, Don M. Benson, Roger G. Ulrich, Brian J. Lannutti, Celeste M. Bello, Brad S. Kahl, Stephen E. Spurgeon, Langdon L. Miller
Publikováno v:
Blood. 123(22)
In a phase 1 trial, idelalisib (GS-1101, CAL-101), a selective inhibitor of the lipid kinase PI3Kδ, was evaluated in 54 patients with relapsed/refractory chronic lymphocytic leukemia (CLL) with adverse characteristics including bulky lymphadenopathy
Autor:
Nilantha S. Sirisoma, Zhiqian Wu, Patrick M. Woster, Robert A. Casero, Heather K Webb, Hyo Chol Ha
Publikováno v:
Journal of Medicinal Chemistry. 42:1415-1421
Polyamine analogues such as bis(ethyl)norspermine and N1-(cyclopropylmethyl)-N11-ethyl-4,8-diazaundecane (CPENSpm) act as potent modulators of cellular polyamine metabolism in vitro and possess impressive antitumor activity against a number of cell l
Publikováno v:
The FASEB Journal. 26